Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vir Biotechnology, Inc.

Latest From Vir Biotechnology, Inc.

Gene Therapy Manufacturing: US FDA Wants Academics Brought ‘Into The Loop’

FDA’s Peter Marks says educating academics about CMC would help them understand why it is necessary to do things in a standardized way. He predicts the field will move away from individual manufacturing platforms in the next five to 10 years.

Gene Therapy Manufacturing

J.P. Morgan Day Four: Roche Sees Lots Of Partnering Interest, While Bluebird, Sage Offer Launch Updates

Daily notebook from the J.P. Morgan Healthcare Conference:  Roche expects continued high interest in partnering; Vir explains cost-cutting gives it a stronger base; bluebird provides Lyfgenia performance to date; Sage details Zurzuvae launch trajectory; and Madrigal lays out next steps in NASH. 

Deals M & A

J.P. Morgan 2024: Optimism With An Undercurrent Of Tension

An uptick in deals and an improving macro-economic outlook laid the groundwork for a rosier sentiment across much of the industry at the annual health care conference.

Business Strategies Gene Therapy

Finance Watch: Syndax Has A Standout Post-ASH Offering As Peers Scramble For Cash

Public Company Edition: Syndax grossed $230m in a follow-on public offering based on positive results for its menin inhibitor in leukemia, but the FOPO was an outlier relative to other companies, which relied on private placements, debt and other options to raise cash in a tough market.

Financing Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Humabs BioMed SA